Novartis to acquire Synnovation Therapeutics PI3Kα inhibitor program for up to USD 3b.

Novartis has agreed to acquire Pikavation Therapeutics, a wholly-owned subsidiary of Synnovation Therapeutics, to gain control of SNV4818 and related PI3Kα inhibitor programs. The Novartis Synnovation acquisition, announced on March 19, 2026, covers a pan-mutant selective PI3K alpha small molecule inhibitor currently in Phase 1/2 trials for HR+/HER2- metastatic breast cancer and other solid tumors. Synnovation is a clinical-stage company headquartered in Wilmington, Delaware, focused on small-molecule targeted therapies in oncology and immunology.

Under the agreement, Novartis will pay Synnovation USD 2 billion in upfront cash and up to USD 1 billion in development, regulatory, and commercial milestone payments, for total potential consideration of up to USD 3 billion. No royalties, profit-sharing arrangements, or equity components were disclosed. The upfront payment represents approximately 67% of the total deal value. The transaction is expected to close in H1 2026, subject to antitrust review under the Hart-Scott-Rodino Act. Novartis will assume sole responsibility for all future development and commercialization of the acquired programs.

Deal context

SNV4818 is a small molecule designed to selectively inhibit multiple oncogenic mutations of PI3Kα while sparing the wild-type enzyme. PIK3CA mutations encoding PI3Kα are among the most common oncogenic alterations in HR+/HER2- breast cancer and occur across other solid tumor types. First-generation PI3Kα inhibitors, including Novartis's own alpelisib, inhibit both mutant and wild-type forms of the enzyme. This lack of mutant selectivity drives on-target toxicities including hyperglycemia, rash, and diarrhea. Pan-mutant selective inhibitors aim to widen the therapeutic window by concentrating activity on the disease-driving mutant protein. A Phase 1/2 trial evaluating SNV4818 as monotherapy and in combination with fulvestrant or palbociclib in patients with advanced PIK3CA-mutant solid tumors is ongoing, with enrollment of 320 participants across sites in Canada and Australia (NCT06736704). No clinical data from this trial have been publicly reported.

For Novartis, this deal represents an effort to defend and extend its position in the PI3Kα pathway. Alpelisib generated the company's initial franchise in PIK3CA-mutant breast cancer but faces displacement by agents with improved tolerability profiles. Acquiring SNV4818 allows Novartis to develop a next-generation successor using its existing breast cancer commercial infrastructure. Synnovation retains its remaining pipeline, including SNV1521, a PARP1-selective inhibitor in Phase 1, along with additional oncology and immunology programs.

The PI3Kα inhibitor landscape has become competitive. Several companies are developing next-generation mutant-selective agents targeting the same biology.

• Tersolisib (STX-478) — Eli Lilly (acquired from Scorpion Therapeutics) — Phase 3 pivotal trial; allosteric, pan-mutant selective, CNS-penetrant
• Zovegalisib (RLY-2608) — Relay Therapeutics — Phase 1/2, with Phase 3 planned; allosteric, pan-mutant and isoform-selective
• OKI-219 — OnKure Therapeutics — Phase 1; mutation-specific (H1047R only)
• LY4045004 — Eli Lilly (internal) — preclinical/early clinical; pan-mutant selective
• Inavolisib (Itovebi) — Roche/Genentech — approved 2024; PI3Kα-selective but not mutant-selective

Lilly's tersolisib is the most advanced next-generation program and has already entered a front-line pivotal study. Relay's zovegalisib showed consistent efficacy and tolerability in updated data presented at ASCO 2025. Lilly's earlier mutation-specific candidate LOXO-783 was discontinued after showing limited monotherapy activity in Phase 1, which has shifted competitive consensus toward pan-mutant approaches. SNV4818 enters this field behind at least two competitors with more advanced clinical data, though Novartis's existing commercial presence in PI3Kα-mutant breast cancer and its global development capabilities could accelerate the program's path through later-stage trials.

---

Spot something wrong? Report an issue with this article